187 related articles for article (PubMed ID: 35994404)
1. Evaluation of the active constituents of Nilavembu Kudineer for viral replication inhibition against SARS-CoV-2: An approach to targeting RNA-dependent RNA polymerase (RdRp).
Kuriakose A; Nair B; Abdelgawad MA; Adewum AT; Soliman MES; Mathew B; Nath LR
J Food Biochem; 2022 Nov; 46(11):e14367. PubMed ID: 35994404
[TBL] [Abstract][Full Text] [Related]
2. A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 patients - a structured summary of a study protocol for a randomized controlled trial.
Srivastava A; Rengaraju M; Srivastava S; Narayan V; Gupta V; Upadhayay R
Trials; 2021 Feb; 22(1):130. PubMed ID: 33573696
[TBL] [Abstract][Full Text] [Related]
3. Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach.
Thirumal Kumar D; Shree Devi MS; Udhaya Kumar S; Sherlin A; Mathew A; Lakshmipriya M; Sathiyarajeswaran P; Gnanasambandan R; Siva R; Magesh R; George Priya Doss C
Adv Protein Chem Struct Biol; 2022; 129():275-379. PubMed ID: 35305722
[TBL] [Abstract][Full Text] [Related]
4. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients-a double-blind, placebo-controlled, clinical trial.
Srivastava A; Rengaraju M; Srivastava S; Narayanan V; Gupta V; Upadhayay R; Kumar J; Parameswaran S; KanakavalliKadarkarai ; AarthiVelmurugan
Trials; 2021 Aug; 22(1):570. PubMed ID: 34454572
[TBL] [Abstract][Full Text] [Related]
6. Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp.
Murali M; Gowtham HG; Ansari MA; Alomary MN; Alghamdi S; Almehmadi M; Singh SB; Shilpa N; Aiyaz M; Kalegowda N; Ledesma AE; Amruthesh KN
Curr Pharm Des; 2022; 28(12):969-980. PubMed ID: 35796443
[TBL] [Abstract][Full Text] [Related]
7. Potential Candidates against COVID-19 Targeting RNA-Dependent RNA Polymerase: A Comprehensive Review.
Agrawal N; Goyal A
Curr Pharm Biotechnol; 2022; 23(3):396-419. PubMed ID: 33882805
[TBL] [Abstract][Full Text] [Related]
8. 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
Zhao J; Zhang G; Zhang Y; Yi D; Li Q; Ma L; Guo S; Li X; Guo F; Lin R; Luu G; Liu Z; Wang Y; Cen S
Antiviral Res; 2021 Dec; 196():105209. PubMed ID: 34801588
[TBL] [Abstract][Full Text] [Related]
9. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
[TBL] [Abstract][Full Text] [Related]
10. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
11. Cyanorona-20: The first potent anti-SARS-CoV-2 agent.
Rabie AM
Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016
[TBL] [Abstract][Full Text] [Related]
12.
Doharey PK; Singh V; Gedda MR; Sahoo AK; Varadwaj PK; Sharma B
J Biomol Struct Dyn; 2022 Aug; 40(12):5588-5605. PubMed ID: 33475021
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods.
Poustforoosh A; Hashemipour H; Tüzün B; Pardakhty A; Mehrabani M; Nematollahi MH
Biophys Chem; 2021 May; 272():106564. PubMed ID: 33711743
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory effect of Kaba Sura Kudineer (AYUSH approved COVID-19 drug)-A Siddha poly-herbal formulation against lipopolysaccharide induced inflammatory response in RAW-264.7 macrophages cells.
Jose SP; M R; S S; Rajan S; Saji S; Narayanan V; S S
J Ethnopharmacol; 2022 Jan; 283():114738. PubMed ID: 34653521
[TBL] [Abstract][Full Text] [Related]
15. Cordycepin as a Promising Inhibitor of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp).
Bibi S; Hasan MM; Wang YB; Papadakos SP; Yu H
Curr Med Chem; 2022; 29(1):152-162. PubMed ID: 34420502
[TBL] [Abstract][Full Text] [Related]
16. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.
Kiran G; Karthik L; Shree Devi MS; Sathiyarajeswaran P; Kanakavalli K; Kumar KM; Ramesh Kumar D
J Ayurveda Integr Med; 2022; 13(1):100324. PubMed ID: 32527713
[TBL] [Abstract][Full Text] [Related]
17. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W
SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307
[TBL] [Abstract][Full Text] [Related]
18. Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India.
Natarajan S; Anbarasi C; Sathiyarajeswaran P; Manickam P; Geetha S; Kathiravan R; Prathiba P; Pitchiahkumar M; Parthiban P; Kanakavalli K; Balaji P
Trials; 2021 Sep; 22(1):623. PubMed ID: 34526104
[TBL] [Abstract][Full Text] [Related]
19. De Novo Potent Peptide Nucleic Acid Antisense Oligomer Inhibitors Targeting SARS-CoV-2 RNA-Dependent RNA Polymerase via Structure-Guided Drug Design.
Shehzadi K; Yu M; Liang J
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139312
[TBL] [Abstract][Full Text] [Related]
20. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
Wakchaure PD; Ghosh S; Ganguly B
J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
